XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Investments and Equity Method Investments (Tables)
 6 Months Ended
Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Investments and Equity Method Investments
Investments consisted of the following (in thousands):
Investments:As of June 30, 2024As of December 31, 2023
SAFEs$18,686 $23,898 
Non-marketable equity securities16,232 22,938 
Marketable equity securities19,698 17,563 
Genomatica preferred stock6,985 11,885 
Synlogic common stock634 1,627 
Synlogic warrants255 654 
Total$62,490 $78,565 
Loss on investments and equity method investments consisted of the following (in thousands):
 Three Months Ended June 30,Six Months Ended June 30,
 2024202320242023
(Loss) gain on investments:
Synlogic common stock$(123)$(1,281)$(993)$(2,092)
Synlogic warrants(49)(514)(399)(841)
Genomatica preferred stock(4,900)— (4,900)— 
Marketable equity securities(1,754)(326)2,134 (3,747)
SAFEs— — (5,212)(1,811)
Total$(6,826)$(2,121)$(9,370)$(8,491)
Loss on equity method investments:
BiomEdit$— $— $— $(1,462)
Other— (67)— (54)
Total$— $(67)$— $(1,516)
The carrying value for non-marketable equity securities accounted for using the fair value measurement alternative and held as of June 30, 2024, including cumulative unrealized losses, were as follows (in thousands):
As of June 30, 2024
Total initial cost$107,996 
Impairment charges(64,465)
Downward adjustments from observable price changes(1,628)
Carrying value$41,903 
Gain (Loss) on Securities
The components of loss on investments for each period were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Impairment charges$(4,900)$— $(10,112)$(1,811)
Ongoing mark-to-market adjustments on marketable equity securities(1,926)(2,121)742 (6,680)
Total loss on investments$(6,826)$(2,121)$(9,370)$(8,491)